143 related articles for article (PubMed ID: 15610661)
21. Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma.
Wu KL; Beksac M; van Droogenbroeck J; Amadori S; Zweegman S; Sonneveld P
Haematologica; 2006 Dec; 91(12):1722-3. PubMed ID: 17145617
[TBL] [Abstract][Full Text] [Related]
22. Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity.
Wu X; Hu Z; Nizzero S; Zhang G; Ramirez MR; Shi C; Zhou J; Ferrari M; Shen H
J Control Release; 2017 Dec; 268():92-101. PubMed ID: 29042320
[TBL] [Abstract][Full Text] [Related]
23. Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide.
Shackelford D; Kenific C; Blusztajn A; Waxman S; Ren R
Cancer Res; 2006 Dec; 66(23):11360-9. PubMed ID: 17145882
[TBL] [Abstract][Full Text] [Related]
24. Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia.
Thomas X; Pigneux A; Raffoux E; Huguet F; Caillot D; Fenaux P
Haematologica; 2006 Jul; 91(7):996-7. PubMed ID: 16757416
[TBL] [Abstract][Full Text] [Related]
25. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells.
Chen GQ; Zhou L; Styblo M; Walton F; Jing Y; Weinberg R; Chen Z; Waxman S
Cancer Res; 2003 Apr; 63(8):1853-9. PubMed ID: 12702573
[TBL] [Abstract][Full Text] [Related]
26. Arsenic and old lace: novel approaches in elderly patients with acute myeloid leukemia.
Roboz GJ
Semin Hematol; 2008 Jul; 45(3 Suppl 2):S22-4. PubMed ID: 18760707
[TBL] [Abstract][Full Text] [Related]
27. A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes.
Wei W; Zhou F; Zhang Y; Guo L; Shi H; Hou J
Leuk Res; 2012 Jun; 36(6):715-9. PubMed ID: 22277680
[TBL] [Abstract][Full Text] [Related]
28. Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence.
Sanz MA; Fenaux P; Lo Coco F;
Haematologica; 2005 Sep; 90(9):1231-5. PubMed ID: 16154847
[TBL] [Abstract][Full Text] [Related]
29. Molecular targets of arsenic trioxide in malignant cells.
Miller WH
Oncologist; 2002; 7 Suppl 1():14-9. PubMed ID: 11961205
[TBL] [Abstract][Full Text] [Related]
30. Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome.
Roboz GJ; Ritchie EK; Curcio T; Samuel M; Provenzano J; Segovia J; Christos PJ; Mathew S; Allen-Bard S; Feldman EJ
Leuk Res; 2011 Apr; 35(4):522-5. PubMed ID: 20956016
[TBL] [Abstract][Full Text] [Related]
31. Signal transduction pathways and transcription factors triggered by arsenic trioxide in leukemia cells.
Sumi D; Shinkai Y; Kumagai Y
Toxicol Appl Pharmacol; 2010 May; 244(3):385-92. PubMed ID: 20193703
[TBL] [Abstract][Full Text] [Related]
32. New data with arsenic trioxide in leukemias and myelodysplastic syndromes.
Sekeres MA
Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 1():S7-S12. PubMed ID: 18282365
[TBL] [Abstract][Full Text] [Related]
33. Arsenic trioxide suppresses thymidylate synthase in 5-FU-resistant colorectal cancer cell line HT29 In Vitro re-sensitizing cells to 5-FU.
Subbarayan PR; Lee K; Ardalan B
Anticancer Res; 2010 Apr; 30(4):1157-62. PubMed ID: 20530422
[TBL] [Abstract][Full Text] [Related]
34. The expanding role of arsenic in acute promyelocytic leukemia.
Tallman MS
Semin Hematol; 2008 Jul; 45(3 Suppl 2):S25-9. PubMed ID: 18760708
[TBL] [Abstract][Full Text] [Related]
35. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study.
Kwong YL; Au WY; Chim CS; Pang A; Suen C; Liang R
Am J Hematol; 2001 Apr; 66(4):274-9. PubMed ID: 11279639
[TBL] [Abstract][Full Text] [Related]
36. Arsenic trioxide in the treatment of haematological malignancies.
Kwong YL
Expert Opin Drug Saf; 2004 Nov; 3(6):589-97. PubMed ID: 15500417
[TBL] [Abstract][Full Text] [Related]
37. New agents in myelodysplastic syndromes.
Jabbour EJ; Giles FJ
Curr Hematol Rep; 2005 May; 4(3):191-9. PubMed ID: 15865871
[TBL] [Abstract][Full Text] [Related]
38. Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia.
Galimberti S; Papineschi F; Carmignani A; Testi R; Fazzi R; Petrini M
Bone Marrow Transplant; 1999 Aug; 24(3):345-8. PubMed ID: 10455379
[TBL] [Abstract][Full Text] [Related]
39. Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid.
Campbell RA; Sanchez E; Steinberg JA; Baritaki S; Gordon M; Wang C; Shalitin D; Chen H; Pang S; Bonavida B; Said J; Berenson JR
Br J Haematol; 2007 Aug; 138(4):467-78. PubMed ID: 17587338
[TBL] [Abstract][Full Text] [Related]
40. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
Quezada G; Kopp L; Estey E; Wells RJ
Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]